Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer

Laboratory Investigation

Volumn 95, Issue 10, 2015, Pages 1197-1206

  Ma, Jie ^a,b   Lin, Yanli ^b   Zhan, Min ^b   Mann, Dean L ^b   Stass, Sanford A ^b   Jiang, Feng ^b  

^a JIANGSU UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 101 3P; MICRORNA 193B 3P; MICRORNA 19B 3P; MICRORNA 29A 3P; MICRORNA 29B 3P; MICRORNA 576 3P; MICRORNA 766 3P; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN19 MICRORNA, HUMAN; MIRN29 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DNA MICROARRAY; EARLY CANCER DIAGNOSIS; FOLLOW UP; GENE EXPRESSION REGULATION; LUNG; LUNG NEOPLASMS; MARYLAND; METABOLISM; MONONUCLEAR CELL; MULTICENTER STUDY; PATHOLOGY;

AGED; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG; LUNG NEOPLASMS; MALE; MARYLAND; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84942787996     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.88     Document Type: Article

References (50)

1. Cancer Facts & Figures 2012. American Cancer Society (ACS). J Consum Health Internet 2012;16:366-367.
2. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
3. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123: 137S-146SS.
4. Ilie M, Hofman V, Long E et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014;2:107.
5. Melief CJ, Finn OJ. Cancer immunology. Curr Opin Immunol 2011;23: 234-236.
6. Keenan B, Jaffee EM. Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance. Ann NY Acad Sci 2013;1284:12-16.
7. Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol 2014;20:11160-11181.
8. Twine NC, Stover JA, Marshall B et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003;63:6069-6075.
9. Bluth M, Lin YY, Zhang H et al. Use of gene expression profiles in cells of peripheral blood to identify new molecular markers of acute pancreatitis. Arch Surg 2008;143:227-233.
10. Baine MJ, Chakraborty S, Smith LM et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One 2011;6:e17014.
11. Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003;100:1896-1901.
12. Sasaki K, Kohanbash G, Hoji A et al. miR-17-92 expression in differentiated T cells-implications for cancer immunotherapy. J Transl Med 2010;8:17.
13. Wang WS, Liu LX, Li GP et al. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) 2013;6:331-338.
14. Ma J, Li N, Guarnera M, Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights 2013;8:127-136.
15. Shen J, Liu Z, Todd NW et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011;11:374.
16. Shen J, Todd NW, Zhang H et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011;91:579-587.
17. Xing L, Su J, Guarnera MA et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res 2015;21:484-489.
18. Shen J, Liao J, Guarnera MA et al. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol 2014;9:33-40.
19. Ralfkiaer U, Hagedorn PH, Bangsgaard N et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011;118: 5891-5900.
20. Ma J, Mannoor K, Gao L et al. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol Oncol 2014;8:1208-1219.
21. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010;127: 2870-2878.
22. Xing L, Todd NW, Yu L et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010;23:1157-1164.
23. Wang J, Tian X, Han R et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 2014;33:1181-1189.
24. Sahai H, Khurshid A. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. Stat Med 1996;15: 1-21.
25. Obuchowski NA, Lieber ML, Wians Jr FH . ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 2004;50: 1118-1125.
26. Shen J, Jiang F. Applications of MicroRNAs in the diagnosis and prognosis of lung cancer. Expert Opin Med Diagn 2012;6:197-207.
27. Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011;108: 3713-3718.
28. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9: 189-198.
29. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-1726.
30. Sozzi G, Boeri M, Rossi M et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014;32:768-773.
31. Jarry J, Schadendorf D, Greenwood C et al. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 2014;8:819-829.
32. Cortez MA, Bueso-Ramos C, Ferdin J et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8: 467-477.
33. Valadi H, Ekstrom K, Bossios A et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-659.
34. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010;107:6328-6333.
35. Wang K, Zhang S, Weber J et al. Export of microRNAs and microRNAprotective protein by mammalian cells. Nucleic Acids Res 2010;38: 7248-7259.
36. Vickers KC, Remaley AT. Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 2012;23:91-97.
37. Fichtlscherer S, De Rosa S, Fox H et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107:677-684.
38. Moldovan L, Batte KE, Trgovcich J et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014;18: 371-390.
39. Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003-5008.
40. Vickers KC, Palmisano BT, Shoucri BM et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-433.
41. Hunter MP, Ismail N, Zhang X et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008;3:e3694.
42. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
43. Showe MK, Vachani A, Kossenkov AV et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with nonsmall cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009;69:9202-9210.
44. Liston A, Papadopoulou AS, Danso-Abeam D et al. MicroRNA-29 in the adaptive immune system: setting the threshold. Cell Mol Life Sci 2012;69:3533-3541.
45. Ma F, Xu S, Liu X et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 2011;12:861-869.
46. Liang Z, Li S, Xu X et al. MicroRNA-576-3p inhibits proliferation in bladder cancer cells by targeting cyclin D1. Mol Cells 2015;38:130-137.
47. Sabarinathan R, Wenzel A, Novotny P et al. Transcriptome-wide analysis of UTRs in non-small cell lung cancer reveals cancer-related genes with SNV-induced changes on RNA secondary structure and miRNA target sites. PLoS One 2014;9:e82699.
48. Zhao Z, Wang L, Song W et al. Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. World J Surg Oncol 2015;13:101.
49. Konno Y, Dong P, Xiong Y et al. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 2014;5: 6049-6062.
50. Hummel R, Sie C, Watson DI et al. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014;20:14904-14912.